1. Home
  2. Live Updates
  3. Research institute translational health science technology

Live Breaking News & Updates on Research institute translational health science technology

Stay informed with the latest breaking news from Research institute translational health science technology on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Research institute translational health science technology and stay connected to the pulse of your community

Biological E likely to submit final data of Corbevax Covid-19 vaccine by November-end: Official sources

Vaccine marker Biological E is likely to submit final data of its Corebevax Covid-19 vaccine to the DGCI by the end of November, health ministry sources said on Thursday.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Bharat , Research-institute-translational-health-science-technology , Central-drug-authority , Union-health-ministry , Biotechnology-industry-research-assistance-council , Expert-committee

Biological E seeks DCGI's nod for phase-3 trial of Corbevax as booster dose for Covishield, Covaxin

Biological E seeks DCGI's nod for phase-3 trial of Corbevax as booster dose for Covishield, Covaxin
indiatoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatoday.in Daily Mail and Mail on Sunday newspapers.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Research-institute-translational-health-science-technology , Union-health-ministry , Biotechnology-industry-research-assistance-council , Aayog-member-health-dr-vk-paul , Expert-committee , Central-drugs-standard-control-organisation

Biological E seeks nod for phase-3 trial of Corbevax as booster dose for Covishield, Covaxin

Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Punit-goenka , Piyush-goyal , Union-health-ministry , Central-drugs-standard-control-organisation , Department-of-biotechnology , Research-institute-translational-health-science-technology , Invesco

Coronavirus Vaccine Booster Dose: Biological E Seeks Regulator's Nod For Phase-3 Trial Of Corbevax As Booster Dose

Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Research-institute-translational-health-science-technology , Union-health-ministry , Biotechnology-industry-research-assistance-council , Aayog-member-health-dr-vk-paul , Expert-committee , Central-drugs-standard-control-organisation

Biological E's COVID-19 vaccine Corbevax likely in October: Dr VK Paul

Biological E's COVID-19 vaccine Corbevax likely in October: Dr VK Paul
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Union-health-ministry , Research-institute-translational-health-science-technology , Government-of-india-department-biotechnology , Controller-general , Evaluate-safety , Corbevax-vaccine

DGCI nod to Biological E to conduct phase 2/3 clinical trials of its COVID-19 vaccine on children between 5 and 18 years

DGCI nod to Biological E to conduct phase 2/3 clinical trials of its COVID-19 vaccine on children between 5 and 18 years
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , New-delhi , Delhi , Zydus-cadila , Research-institute-translational-health-science-technology , Serum-institute-of-india , Expert-committee , Health-ministry

DCGI approves phase 2, 3 trials of Biological E's COVID-19 vaccine for 5-18 years

DCGI approves phase 2, 3 trials of Biological E's COVID-19 vaccine for 5-18 years
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Zydus-cadila , Research-institute-translational-health-science-technology , Serum-institute-of-india , Expert-committee , Health-ministry , Department-of-biotechnology , Drugs-controller-general

Mansukh Mandaviya holds meeting with Biological-E MD on progress of Covid vaccine Corbevax

Mansukh Mandaviya holds meeting with Biological-E MD on progress of Covid vaccine Corbevax
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Mahima-dalta , Satish-reddy , Mahima-datla , Research-institute-translational-health-science-technology , Union-health , Union-health-ministry , Union-ministry-of-health

Health Minister Mansukh Mandaviya Meets Top Vaccine Bosses From SII, Biological-E, Dr Reddy's

Health Minister Mansukh Mandaviya Meets Top Vaccine Bosses From SII, Biological-E, Dr Reddy's
ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Mahima-dalta , Adar-poonawalla , Satish-reddy , Mahima-datla , Mansukh-mandaviya , Union-health , Union-ministry-of-health

Centre finalises deal with Hyderabad-based firm for 30 crore Covid vaccine doses


URL copied
Centre finalises advance deal with Hyderabad-based firm for 30 crore Covid vaccine doses
The Union Ministry of Health has finalised arrangements with Hyderabad based vaccine manufacturer Biological-E to reserve 30 crore of COVID-19 vaccine doses. These vaccine doses will be manufactured and stockpiled by M/s Biological-E from August-December 2021. 
For this purpose, the Union Ministry of Health would be making an advance payment of Rs. 1500 crore to M/s Biological-E. 
The COVID-19 vaccine of Biological-E is currently undergoing Phase-3 clinical trial after showing promising results in Phase 1 and 2 clinical trials. The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months. 

Faridabad , Haryana , India , Hyderabad , Andhra-pradesh , Research-institute-translational-health-science-technology , Union-ministry-of-health , National-expert-group-on-vaccine-administration , Vaccine-development-mission , Research-development , Department-of-biotechnology